Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BNXTFNYSE:CYBNNASDAQ:ENGNNYSE:IKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNXTFBioNxt Solutions$0.41+3.6%$0.37$0.11▼$0.43$47.95M0.771,647 shs1,028 shsCYBNCybin$7.98+8.1%$7.62$4.81▼$13.88$183.62M0.68279,729 shs442,098 shsENGNenGene$3.88+3.7%$3.62$2.65▼$11.00$194.20M-0.42128,170 shs45,357 shsIKTInhibikase Therapeutics$1.89+2.2%$1.94$1.12▼$4.20$140.51M0.92275,891 shs81,965 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNXTFBioNxt Solutions0.00%+18.68%+3.27%+38.07%+83.65%CYBNCybin0.00%-2.15%-7.05%+40.16%+2,061.25%ENGNenGene0.00%+6.01%+1.31%-13.78%-56.84%IKTInhibikase Therapeutics0.00%+16.67%-4.55%+2.72%+64.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNXTFBioNxt SolutionsN/AN/AN/AN/AN/AN/AN/AN/ACYBNCybin2.7481 of 5 stars3.60.00.00.02.50.81.3ENGNenGene2.6403 of 5 stars3.53.00.00.00.92.50.6IKTInhibikase Therapeutics1.378 of 5 stars3.31.00.00.01.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNXTFBioNxt Solutions 0.00N/AN/AN/ACYBNCybin 3.25Buy$86.00978.37% UpsideENGNenGene 3.00Buy$23.29500.15% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50243.92% UpsideCurrent Analyst Ratings BreakdownLatest BNXTF, CYBN, ENGN, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025CYBNCybinCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/29/2025ENGNenGeneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNXTFBioNxt Solutions$20K2,397.39N/AN/A($0.04) per share-10.36CYBNCybinN/AN/AN/AN/A$10.83 per shareN/AENGNenGeneN/AN/AN/AN/A$4.45 per shareN/AIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNXTFBioNxt Solutions-$3.80M-$0.04N/A∞N/A-19,165.00%N/A-616.01%N/ACYBNCybin-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/AENGNenGene-$55.14M-$1.65N/AN/AN/AN/A-32.60%-28.26%N/AIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/ALatest BNXTF, CYBN, ENGN, and IKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/26/2025Q1 2025BNXTFBioNxt SolutionsN/A-$0.01N/A-$0.01N/AN/A6/10/2025Q2 2025ENGNenGene-$0.4768-$0.51-$0.0332-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNXTFBioNxt SolutionsN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNXTFBioNxt SolutionsN/AN/AN/ACYBNCybinN/A24.2424.24ENGNenGene0.0912.6612.66IKTInhibikase TherapeuticsN/A0.850.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNXTFBioNxt SolutionsN/ACYBNCybin17.94%ENGNenGene64.16%IKTInhibikase Therapeutics3.81%Insider OwnershipCompanyInsider OwnershipBNXTFBioNxt SolutionsN/ACYBNCybin15.00%ENGNenGene10.40%IKTInhibikase Therapeutics7.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNXTFBioNxt Solutions20115.76 millionN/ANot OptionableCYBNCybin5023.02 million17.96 millionNot OptionableENGNenGene3151.10 million45.79 millionN/AIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableBNXTF, CYBN, ENGN, and IKT HeadlinesRecent News About These CompaniesIKT Inhibikase Therapeutics, Inc. - Seeking AlphaJuly 3 at 8:12 PM | seekingalpha.comInhibikase Therapeutics (NYSE:IKT) Trading Down 5.1% - What's Next?July 3 at 3:27 AM | marketbeat.comInhibikase Therapeutics shareholders elect directors and approve equity plan changesJuly 2 at 7:44 AM | investing.comInhibikase Therapeutics Insiders Placed Bullish Bets Worth US$2.70mJune 30, 2025 | finance.yahoo.comMillennium Management LLC Invests $462,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT)June 10, 2025 | marketbeat.comInhibikase Therapeutics Reports Q1 2025 Financial ResultsMay 22, 2025 | tipranks.comInhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent ActivityMay 14, 2025 | finance.yahoo.comInhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent ActivityMay 14, 2025 | globenewswire.comFormer Inhibikase leader launches new biotech for midstage Parkinson’s assetMay 12, 2025 | fiercebiotech.comFWhy Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Up 6.22%May 9, 2025 | aaii.comASHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)May 5, 2025 | prnewswire.comInhibikase Therapeutics: A Hold With Uncertain Prospects In PAHMay 2, 2025 | seekingalpha.comWhy Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Down 5.30%April 17, 2025 | aaii.comAInhibikase Therapeutics Appoints David McIntyre As CFO, Stock Up In Pre-marketApril 16, 2025 | nasdaq.comInhibikase Therapeutics Advances PAH Treatment with New LeadershipApril 14, 2025 | tipranks.comInhibikase Therapeutics announces appointment of McIntyre as CFOApril 14, 2025 | markets.businessinsider.comInhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial OfficerApril 14, 2025 | globenewswire.comWhy Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Down 14.13%April 8, 2025 | aaii.comAHedge funds owners may consider drastic measures as Inhibikase Therapeutics, Inc.'s (NASDAQ:IKT) recent US$29m drop adds to long-term lossesApril 4, 2025 | finance.yahoo.comInhibikase Therapeutics (IKT) Receives a Hold from H.C. WainwrightMarch 29, 2025 | markets.businessinsider.comInhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent ActivityMarch 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBNXTF, CYBN, ENGN, and IKT Company DescriptionsBioNxt Solutions OTCMKTS:BNXTF$0.41 +0.01 (+3.55%) As of 07/3/2025 10:42 AM EasternBioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.Cybin NYSE:CYBN$7.98 +0.60 (+8.06%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$7.96 -0.01 (-0.19%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.enGene NASDAQ:ENGN$3.88 +0.14 (+3.74%) As of 07/3/2025 03:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Inhibikase Therapeutics NYSE:IKT$1.89 +0.04 (+2.16%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
